

Ant
B25

in binding to other proteins involved in novel signaling pathway(s) leading to apoptosis. It is not known whether the C-terminal region of Apop3 is able to bind directly to known death adaptor or death protease. Additional two-hybrid screening using Apop3 as bait is being carried out to find signaling proteins downstream of Apop3.-

On page 51, immediately preceding the heading "CLAIMS", please insert the enclosed text entitled "SEQUENCE LISTING".

IN THE CLAIMS

- SVB
C1
B26
1. (Twice Amended) 1. A recombinant nucleic acid encoding an Apop3 protein that comprises an amino acid sequence at least 85% identical to the amino acid sequence depicted in Figure 6 (SEQ ID NO:6).
 2. (Twice Amended) A recombinant nucleic acid according to claim 1 comprising the nucleotide sequence depicted in Figure 5 (SEQ ID NO:5) or its complement.
 3. (Twice Amended) A recombinant nucleic acid according to claim 1 wherein said nucleic acid hybridizes under high stringency conditions to the nucleotide sequence depicted in Figure 5 (SEQ ID NO:5) or its complement.
 4. (Twice Amended) A recombinant nucleic acid according to claim 1 wherein said nucleic acid comprises a nucleotide sequence at least 85% identical to the nucleotide sequence depicted in Figure 5 (SEQ ID NO:5) or its complement.
 5. (Twice Amended) A recombinant nucleic acid according to claim 1 wherein said Apop3 protein comprises the amino acid sequence depicted in Figure 6 (SEQ ID NO:6).-
 6. A recombinant nucleic acid according to claim 1 wherein said Apop3 protein is a human Apop3 protein.
 7. (Twice Amended) A recombinant nucleic acid comprising nucleotides 1-822 depicted in Figure 5 (SEQ ID NO:5), or its complement.
 8. A recombinant nucleic acid according to claim 1 operably linked to control sequences recognized by a host cell transformed with the nucleic acid.

9. An expression vector comprising the nucleic acid of claim 1.
10. A host cell comprising the nucleic acid of claim 1.
11. A host cell comprising the expression vector of claim 9.
12. (Twice Amended) A recombinant Apop3 protein comprising an amino acid sequence at least 85% identical to the amino acid sequence depicted in Figure 6 (SEQ ID NO:6).
13. (Twice Amended) An Apop3 protein according to claim 12 comprising the amino acid sequence depicted in Figure 6 (SEQ ID NO:6).
14. (Twice Amended) An Apop3 protein according to claim 12 wherein said Apop3 protein is encoded by a nucleic acid comprising the nucleotide sequence depicted in Figure 5 (SEQ ID NO:5) or its complement.
15. (Twice Amended) An Apop3 protein according to claim 12 wherein said Apop3 protein is encoded by a nucleic acid which nucleic acid comprises a nucleotide sequence at least 85% identical to the nucleotide sequence depicted in Figure 5 (SEQ ID NO:5) or its complement.
16. (Twice Amended) An Apop3 protein according to claim 12 wherein said Apop3 protein is encoded by a nucleic acid which nucleic acid will hybridize under high stringency conditions to the nucleotide sequence depicted in Figure 5 (SEQ ID NO:5) or its complement.
17. An Apop3 protein according to claim 12 wherein said Apop3 protein is a human Apop3 protein.
18. (Twice Amended) A recombinant Apop3 protein comprising the amino acid sequence 1-274 depicted in Figure 6 (SEQ ID NO:6).
19. A process for producing an Apop3 protein according to claim 12 comprising culturing the host cell of claim 10 under conditions suitable for expression of said Apop3 protein.
20. A process according to claim 19, further comprising recovering said Apop3 protein.
21. A monoclonal antibody which specifically binds to an Apop3 protein according to claim 12.

Cont
B26

22. A monoclonal antibody according to claim 21 that reduces or eliminates the biological function of said Apop3 protein.

23. A method for screening for a bioactive agent capable of binding to an Apop3 protein according to claim 12, said method comprising:

- a) combining said Apop3 protein and a candidate bioactive agent; and
- b) determining the binding of said candidate bioactive agent to said Apop3 protein.

24. A method for screening for a bioactive agent capable of interfering with the binding of an Apop3 protein according to claim 12 and RIP, said method comprising:

- a) combining said Apop3 protein, a candidate bioactive agent and a RIP protein; and
- b) determining the binding of said Apop3 protein and said RIP protein.

sub
c1

25. A method for screening for a bioactive agent capable of modulating the activity of an Apop3 protein according to claim 12, said method comprising the steps of:

- a) adding a candidate bioactive agent to a cell comprising a recombinant nucleic acid encoding said Apop3 protein; and
- b) determining the effect of the candidate bioactive agent on apoptosis.

26. A method according to claim 25 wherein a library of candidate bioactive agents is added to a plurality of cells comprising a recombinant nucleic acid encoding said Apop3 protein.—

REMARKS

The specification and claims have been amended to include a Sequence Listing and proper reference to the sequences therein. A "clean" version of the now-pending claim set is provided above. Attached hereto is a marked-up version of the changes made to the specification and claims by the current amendment. The attached page is captioned "Version with markings to show changes made."

Entry of this Amendment is respectfully requested. These amendments are made in adherence with 37 C.F.R. § 1.821-1.825. This amendment is accompanied by a floppy disk containing the above named sequence, SEQUENCE ID NUMBERS 1-10, in computer readable form, and a paper copy of the sequence information. The computer readable sequence listing was prepared through